Predicting Progression and Survival Outcomes for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy: Development and Validation of Robust Prognostic Nomograms

Stereotactic ablative radiotherapy (SABR) has been the standard treatment for medically inoperable patients with early-stage non-small cell lung cancer (ES-NSCLC); however, clinical outcomes after SABR vary significantly among studies. Yet as we transition into the era of personalized medicine, the ability to predict the prognoses of these patients is essential to guide clinical decision-making.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research